Forest Laboratories, Inc. and Cypress Bioscience, Inc. has announced that Savella, a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th.
In January 2009, Savella became the thrid medication to receive FDA approval for the treatment of fibromyalgia. Then in March the manufacturers submitted a minor post-approval cosmetic formulation change to the FDA, which delayed the drug's shipment. Now the FDA has approved the change and the long-awaited Savella will be available to consumers in a matter of days.
If you'd like to know more about Savella (generic name milnacipran), read: FDA Approves Third Medication for Fibromyalgia
Published On: April 22, 2009